% | $
Quotes you view appear here for quick access.

Advaxis, Inc. Message Board

jckrdu 8 posts  |  Last Activity: Jun 23, 2016 4:40 PM Member since: Feb 27, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    BJ's response to the trial timeline in Japan.

    by quicktwosmile Jun 23, 2016 9:42 AM
    jckrdu jckrdu Jun 23, 2016 4:40 PM Flag

    Maybe, but that's not what BJ just told us.

    BJ's response pretty clearly states (last paragraph) that the full trial will need to be run to completion in Japan, and at that point - based on the strength of the results seen - Helios will then decide whether to apply for conditional or full approval.

    I suppose anything's possible, but the language used indicates that the full stroke study needs to be run to completion before either conditional or full approval will be applied for.

    Sentiment: Buy

  • Reply to

    Stock offering announced at what price

    by shaw2.kind Jun 15, 2016 4:40 PM
    jckrdu jckrdu Jun 15, 2016 4:47 PM Flag

    I'm going to say no lower than $2.25.

    An insider recently bought 20,000 shares at $2.49, so I'll be surprised if they do this offering at any less than $2.25.

    Decent PTSD results recently released, and they're moving into Phase 3. There could be some institutional investors that wanted more shares, and didn't want to drive the price up (low float stock) buying on the open market.

    If TNXP can raise some capital at $2.25 or higher - with no warrants in the deal - it could turn out well with Phase 3 fibro data coming around the corner.

    Sentiment: Hold

  • Reply to

    ASCO - did nothing for our PPS

    by aoutdoors562000 Jun 10, 2016 11:10 AM
    jckrdu jckrdu Jun 10, 2016 6:32 PM Flag

    The recent run from $7 to $10, and now a (expected) pullback to $8.50 was part of the "ASCO move", IMO. So, IMO, overall we're up about 20% from $7 to $8.50.

    I like the 3 month and 1 year charts as they still show the recent general uptrend; a big move from $7 to $10 followed by a not uncommon 50% retrace to the midpoint ($8.50ish) of that recent move higher.

    Need to see some consolidation at $8.50ish next week, hopefully with some additional news. Expectation of news at or before Investor Day on 6/28 should keep buying pressure steady, and hopefully keep any large sellers away. GL all.

    Sentiment: Strong Buy

  • Reply to

    This wants to break out above ten !

    by marventrimble Jun 6, 2016 10:50 AM
    jckrdu jckrdu Jun 6, 2016 11:07 AM Flag

    I tend to agree... not sure how high we'll go and how fast, but I agree ADXS should move above $10 in the days/weeks ahead. Today's results, while based on a limited data set, were impressive and provide another data point validating the entire platform. IMO, institutional investors will view this data as another de-risking event, and will start to accummulate more shares. GL all.

    Sentiment: Strong Buy

  • Reply to

    Last 30 minutes of trading today

    by blinn2008 Jun 3, 2016 4:33 PM
    jckrdu jckrdu Jun 4, 2016 8:00 PM Flag

    "Over the years" ADXS has only been a company with Phase 1 trials, and not many results from Phase 2. As the years have passed, ADXS' trials are starting to produce more Phase 2 data and will be moving into Phase 3. More and more air has been pumped into the balloon. How ADXS has traded in past years may not be how it trades with Phase 3 coming soon. IMO, the move up from $9ish to $12ish will be quick and will be the new base. I don't know if this news on 6/6 will be the news that does it, but I can be patient and will continue to slowly accumulate under $10.

    Agree with others that ADXS needs to ink that first big deal with big pharma to start closing the gap to Aduro's market cap. Not sure we'll see the $15-$20 range hold without the signing of a major deal, even if 6/6 ASCO data is great.

    Sentiment: Strong Buy

  • Reply to

    Any thoughts...

    by williamjay63 May 27, 2016 9:59 AM
    jckrdu jckrdu May 27, 2016 10:55 AM Flag

    Got back in ADXS on the pullback on the ADRO news. I held ADXS many years ago, but sold before the big move from $3 to $30. I like how things are setting up here. We'll see how much love the market gives us on the 6/6 cervical data news.

    ADXS has been trading with the IBB index for awhile... you can see the correlation, especially on the 5 day charts. Let's hope the IBB continues its uptrend so we have tailwinds going into ASCO.

    Starting to see a bit of an inverse head-and-shoulders pattern on the 5-day chart, which is a bullish pattern. GL all.

    Sentiment: Strong Buy

  • Reply to

    Over 30M in cash on hand!!!!! WOW!

    by unemonl May 5, 2016 4:20 PM
    jckrdu jckrdu May 6, 2016 8:17 AM Flag

    - Per the financials released yesterday and the 10Q this morning, they burn around $9 million per quarter, which means they have about 3 quarters of cash left on the balance sheet. I wouldn't characterize that as a "great" cash position.
    - Also, per the 10Q, R&D expenses are expected to increase in 2016 as they ramp-up manufacturing.

    I'm not too worried about near-term significant additional dilution, as...
    - They have the $30M line with Aspire and will tap it as needed. They raised $400k in Q1 by selling about 200k shares. That will continue, per the 10Q.
    - Per the 10Q, there are 3.6M warrants out there at $2.48. If exercised, they'll raise and additional $8M with some dilution, but minimal.
    - All that said, Gil still needs to close another partnership deal in 2016 to beef up the cash on the balance sheet. Very doable in 2016 with Helios deal expanson/ARDs, GvHD deal, and/or a deal for stroke in the EU.

    Sentiment: Hold

  • jckrdu jckrdu May 5, 2016 7:43 PM Flag

    Per the CEO, their ramping up manufacturing capacity to support anticipated demand / shipments to some of their customers. Per the CEO, by mid-2017 they expect to be shipping products to some of their customers (CEO mentioned Kite) that should be commercializing products in current Phase 3 or pivotal Phase 2 trials.

    Revenues will ramp significantly in 2017 if just 1 customer (like Kite) gets FDA approval.

    Sentiment: Strong Buy

8.42+1.12(+15.34%)Jun 28 4:00 PMEDT